Patent classifications
C07C233/20
N-acylethanolamide derivatives and uses thereof
The present disclosure provides certain N-Acylethanolamide derivatives, and uses relating thereto.
N-acylethanolamide derivatives and uses thereof
The present disclosure provides certain N-Acylethanolamide derivatives, and uses relating thereto.
COMPOSITION OF ACYLETHANOLAMIDES FROM OLIVE OIL FATTY ACIDS
A composition of acylethanolamides is obtained from olive oil fatty acids and is used in treating neuroinflammation. The acylethanolamide complex includes (weight percentages):
TABLE-US-00001 oleoylethanolamide (OEA) C18:1 60-65% palmitoylethanolamide (PEA) C16:0 5-20% linoleylethanolamide (LEA) C18:2 5-20% stearoylethanolamide (SEA) C18:0 1-2% palmitoylethanolamide (POEA) C16:1 0.1-0.8% myristoylethanolamide (MEA) C14:0 0.02-0.15% mixture of glycerides 4-6% glycerol .sup. 6-8%.
A method obtains the acylethanolamide complex and formulations contain the acylethanolamide complex.
COMPOSITION OF ACYLETHANOLAMIDES FROM OLIVE OIL FATTY ACIDS
A composition of acylethanolamides is obtained from olive oil fatty acids and is used in treating neuroinflammation. The acylethanolamide complex includes (weight percentages):
TABLE-US-00001 oleoylethanolamide (OEA) C18:1 60-65% palmitoylethanolamide (PEA) C16:0 5-20% linoleylethanolamide (LEA) C18:2 5-20% stearoylethanolamide (SEA) C18:0 1-2% palmitoylethanolamide (POEA) C16:1 0.1-0.8% myristoylethanolamide (MEA) C14:0 0.02-0.15% mixture of glycerides 4-6% glycerol .sup. 6-8%.
A method obtains the acylethanolamide complex and formulations contain the acylethanolamide complex.
TRPV1 AGONIST AND PREPARATION METHOD THEREFOR AND USE THEREOF
A compound is represented by formula I. A stereoisomer, tautomer, solvate, polymorph of the compound or a pharmaceutically acceptable salt of the compound, a pharmaceutical composition containing the compound, a preparation method of the compound, and the medical use of the compound are provided.
##STR00001##
TRPV1 AGONIST AND PREPARATION METHOD THEREFOR AND USE THEREOF
A compound is represented by formula I. A stereoisomer, tautomer, solvate, polymorph of the compound or a pharmaceutically acceptable salt of the compound, a pharmaceutical composition containing the compound, a preparation method of the compound, and the medical use of the compound are provided.
##STR00001##
Compositions and methods for treating atherosclerotic cardiovascular disease
The present invention relates to lyso-diacylglyceryltrimethylhomoserine (lyso-DGTS) or derivatives thereof for use in the treatment of atherosclerotic cardiovascular disease, and further provides particular such lyso-DGTS derivatives.
Polymerizable absorbers of UV and high energy visible light
Described are polymerizable high energy light absorbing compounds of formula I: ##STR00001##
wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, and X are as described herein. The compounds absorb various wavelengths of ultraviolet and/or high energy visible light and are suitable for incorporation in various products, such as biomedical devices and ophthalmic devices.
CHEMICAL COMPOUNDS TARGETING THE EYE AND USE THEREOF IN THE TREATMENT OF EYE DISEASES
Disclosed is chemical compounds C that are derivatives of norbixin and have tropism for the eye, and are intended to be used in the treatment of eye diseases in mammals, in particular in the context of altering the retinal pigment epithelium and more particularly in the context of age-related macular degeneration (AMD) and Stargardt's disease.
Hybrid carriers for nucleic acid cargo
A composition for the delivery of a nucleic acid compound is provided which comprises a cationic peptide or polymer and a lipidoid compound. The nucleic acid compound may be any chemically modified or unmodified DNA or RNA. The amount of the lipidoid in the composition is preferably low, relative to the cationic peptide or polymer.